Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Law Offices of Howard G. Smith announces that it is investigating whether Allion Healthcare, Inc.'s ("Allion" or the "Company") (NASDAQ: ALLI) directors complied with their...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Allion Healthcare, Inc. (“Allion” or the “Company”...
Attorney Advertising. Notice is hereby given that Stull, Stull & Brody has commenced an investigation on behalf of shareholders of Allion Healthcare, Inc. (“Allion” or the...
Attorney Advertising. The law firm of Wolf Haldenstein Adler Freeman & Herz LLP is investigating possible breaches of fiduciary duty by the Board of Directors of Allion...
Levi & Korsinsky is investigating the Board of Directors of Allion Healthcare, Inc. (“Allion” or the “Company”) (NasdaqGM: ALLI) for possible breaches of fiduciary duty and...
Allion Healthcare, Inc. (NASDAQ: ALLI) today announced that it has entered into a definitive merger agreement for the Company to be acquired and taken private by an affiliate of...
Allion Healthcare (NASDAQ: ALLI): Second Quarter Highlights Net sales increased 15.3% to $100 million from $86 million Specialty HIV net sales increased 9.4% to $75...
Allion Healthcare, Inc. (NASDAQ: ALLI), today announced that it has entered into a partnership with Being Alive San Diego to launch a Community Learning Center in San Diego...
Allion Healthcare, Inc. (NASDAQ: ALLI), today announced that it will release its financial results for the second quarter ended June 30, 2009, after the close of U.S. financial...
Allion Healthcare (NASDAQ: ALLI): Fully Diluted EPS Guidance increased to $0.50 to $ 0.52 per share Net sales increased 48% to $96.6 million from $65.3 million Net...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
